Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.63 |
| ▸ | PPARG | P37231 | 11/20 | 0.63 |
| ▸ | PPARD | Q03181 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1429551 | 1.00 | PPARA (0.63) | PPARAPPARGPPARDMAPTSYK | |
| SCHEMBL6766498 | 1.00 | PPARA (0.63) | PPARAPPARGPPARDMAPTSYK | |
| SCHEMBL7344730 | 0.96 | PPARA (0.60) | PPARAPPARGPPARDMAPTSYK | |
| SCHEMBL7420961 | 0.94 | PPARA (0.61) | PPARAPPARGPPARDMAPTSYK | |
| SCHEMBL7420964 | 0.94 | PPARA (0.61) | PPARAPPARGPPARDMAPTSYK | |
| SCHEMBL1429859 | 0.94 | PPARA (0.54) | PPARAPPARGPPARDMAPTSYK | |
| SCHEMBL15890596 | 0.93 | PPARA (0.53) | PPARAPPARGPPARDMAPTSYK | |
| SCHEMBL10833222 | 0.91 | MAPT (0.55) | PPARAPPARGPPARDMAPTSYK | |
| SCHEMBL10825320 | 0.91 | MAPT (0.55) | PPARAPPARGPPARDMAPTSYK | |
| SCHEMBL7424826 | 0.90 | PPARA (0.58) | PPARAPPARGPPARDMAPTSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688645-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20160251324-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (FR) | 2016-09-01 | — | — | US | disclosed |
| US-9309207-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2016-04-12 | — | — | US | disclosed |
| US-20160024033-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (FR) | 2016-01-28 | — | — | US | disclosed |
| US-9126955-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20140206760-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI (FR) | 2014-07-24 | — | — | US | disclosed |
| US-8722655-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20140039011-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI (FR) | 2014-02-06 | — | — | US | disclosed |
| US-8580777-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-6716843-B2 | INHIBITOR OF DIPEPTIDYL-PEPTIDASE IV | LES LABORATOIRES SERVIER (FR) | 2004-04-06 | — | — | US | disclosed |
| US-20030087950-A1 | New alpha-amino acid sulphonyl compounds | LES LABORATOIRES SERVIER (FR) | 2003-05-08 | — | — | US | disclosed |
| EP-1245568-A1 | Sulfonyl derivatives of amino acids and their use as inhibitors of dipeptidyl-peptidase IV (DPP IV) | Les Laboratoires Servier (FR) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024033-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | PPARA 2356/4885PPARG 2483/4885PPARD 2318/4885 |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINC1 | PPARA 2356/4885PPARG 2483/4885PPARD 2318/4885 |
| US-20140039011-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | PPARA 2356/4885PPARG 2483/4885PPARD 2318/4885 |
| US-20030087950-A1 | New alpha-amino acid sulphonyl compounds | DNPEP, DPP4, DPP7 | PPARA 1224/4885PPARG 1663/4885PPARD 1426/4885 |
| US-20140206760-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | PPARA 2357/4885PPARG 2493/4885PPARD 2313/4885 |
| US-20160251324-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | PPARA 2356/4885PPARG 2483/4885PPARD 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.